ODE III dermatology office director
Susan Walker will head FDA's Office of Drug Evaluation III Division of Dermatology & Dental Products within the Center for Drug Evaluation & Research, replacing Jonathan Wilkin who retired in September. Walker's wide-ranging agency experience includes service as director of the Division of Dietary Supplement programs in the Office of Nutritional Products, Labeling & Dietary Supplements in CFSAN and deputy director on detail to the Division of General, Restorative & Neurological Devices in the Office of Device Evaluation in CDRH. She has also previously worked for the dermatology office as medical officer and later as medical team leader...
You may also be interested in...
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. London, UK-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.
Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.